Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...

Number 4: The FDA has granted approval for Shanghai Henlius Biotech’s trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02), for the treatment of HER2-positive breast cancer. The approval marks ...

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it ...

April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of ...

During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at ...

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast ...

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on ...

Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that ...

Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a ...

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine ...

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network saved upwards of ...